Vilon
Ultrashort thymic bioregulator; Mostly Russian/Eastern European preclinical and low-certainty clinical literature
Brief Overview: Vilon is a two-amino-acid peptide: lysine plus glutamic acid, abbreviated Lys-Glu or KE. It is usually marketed as a thymus/immune-aging bioregulator. It is not the same as thymosin alpha-1, thymalin, thymogen, or hCG/hMG. Evidence lens: Vilon has a real paper trail, but much of it is old, small, Russian-language, cell-culture, animal, or single-research-network literature. The useful way to read it is as an immune and gene-expression research peptide, not as a proven rejuvenation or cancer-prevention therapy. How to read this: if you're new, focus on identity and evidence quality. Once you're past the basics, separate three claims: immunomodulation, chromatin/gene-expression effects, and lifespan/tumor findings in animals. These are related hypotheses, not a single proven human outcome.
- Vilon is L-lysyl-L-glutamic acid, a synthetic dipeptide usually written as Lys-Glu or KE.
- PubChem lists lysylglutamic acid with formula C11H21N3O5 and molecular weight about 275.30 g/mol.
- Some databases also list lysylglutamic acid dihydrate under names such as Lys-Glu dihydrate, lysine glutamate dihydrate, and Vilon dihydrate.
- Vilon is part of the short-peptide or Khavinson bioregulator family, a group of ultrashort peptides studied mainly for tissue-specific regulation, gene expression, chromatin organization, immune signaling, and aging-related models.
- Vilon is generally framed as thymic or immunomodulatory, while Epithalon is pineal/telomere-oriented, Thymogen is Glu-Trp, and Thymalin is a broader thymic peptide complex rather than a single dipeptide. Because Vilon contains only two amino acids, it does not behave like a large protein hormone.
- Its proposed biology is less about receptor saturation and more about short-peptide signaling, gene-expression effects, or cellular regulatory models. Those mechanisms remain incompletely validated by modern human pharmacology.
- Vilon is a short dipeptide bioregulator associated with immune and aging claims in regional literature. It is not a proven geroprotective drug.
- The central Vilon hypothesis is immunomodulation.
- Older and newer studies describe effects on thymus-cell culture, splenocytes, interleukin-2 expression, T-cell-related activity, macrophage/monocyte behavior, cytokine signaling, and inflammatory adhesion pathways.
- The common claim is not blanket immune stimulation; It is immune normalization or modulation.
- A second hypothesis is gene-expression and chromatin regulation.
- Some short-peptide literature reports changes in chromatin decondensation, ribosomal-gene activity, DNA-microarray expression patterns, and other epigenetic-like effects.
- These findings are interesting but warrant careful interpretation, because many studies are small, model-specific, and not independently replicated at modern drug-development standards.
- Vilon is not a direct cytokine drug, antiviral, vaccine substitute, or immune-booster supplement.
- The more careful statement is that Lys-Glu has been studied as an ultrashort bioregulator that may influence immune-cell signaling and gene-expression patterns in experimental systems.
- Proposed mechanisms include gene-expression modulation and thymic/immune bioregulation. These are broad hypotheses or regional research findings, not settled conclusions. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Human and animal thymus-cell culture: A 2013 Bulletin of Experimental Biology and Medicine paper reported immunomodulating effects of Vilon and an analog in cultures of human and animal thymus cells. This supports a thymic-immune research rationale, but culture response is not the same as clinical immune restoration.
- Inflammation and monocyte/macrophage models: A 2022 in-vitro THP-1 study evaluated several Khavinson peptides including Vilon. The study reported modulation of proliferative and inflammatory pathways, including effects on TNF, IL-6, STAT signaling, extracellular vesicles, and immune-cell adhesion in the model. This is mechanistic evidence, not human therapeutic proof.
- Gene expression and chromatin: DNA-microarray and chromatin-reactivation papers reported that Vilon and related short peptides can alter gene-expression patterns or chromatin organization in experimental cells. These findings help explain why Vilon is discussed as an epigenetic bioregulator, but they do not establish a measurable anti-aging outcome in humans.
- Animal aging and tumor models: Mouse studies reported effects on biological age, lifespan, spontaneous tumor growth, and bladder carcinogenesis models. One rat bladder-carcinogenesis study reported tumor development in 56% of Vilon-treated animals compared with 75.5% of controls. These data justify research interest but are not proof that Vilon prevents cancer in humans.
- GI and renal animal models: Vilon and Epithalon have been studied in aged-rat intestinal transport/enzyme models, and Vilon has been studied in chronic renal failure rat models with effects on transforming growth factor-beta and microvessel permeability. These are animal physiology findings, not renal or gut treatment protocols.
- Evidence is mainly Eastern European/Russian bioregulator literature, preclinical reports, and small human-context claims. It is low confidence compared with approved peptides. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Preclinical Vilon/Lys-Glu tumor/lifespan context [Animal/Preclinical]; Route: Animal/preclinical administration; Exact regimen not standardized from abstract; Dose: Dose details not fully extractable from abstract/snippet; Frequency: Preclinical study-specific; Duration: Preclinical study context; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Community standard 10 mg cycle [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 10 mg; Frequency: Once daily; Duration: 5–10 days; Repeat every 3–6 months; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Community gradual dose protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 67 mcg – 333 mcg in first cycle; 333 mcg – 667 mcg in later cycles; Frequency: Once daily during dosing days; Duration: 5 days, then rest for remainder of 4-week cycle; Repeat monthly; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 4: Biohacker 10 mg monthly/biannual cycle [Community/Biohacker/Anecdotal]; Route: Subcutaneous or intramuscular; Dose: 10 mg; Frequency: Once daily; Duration: 5–10 days per month, or 10 days twice yearly; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Community and regional cycles are empirical. Route and product matter in any protocol, because small peptides may be used orally, injectable, or in other formats with different assumptions. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not calculable from available human data.
- Half-life basis: no validated human route-specific half-life was identified. Because Vilon is a dipeptide, enzymatic hydrolysis and transporter effects are plausible, but a reliable steady-state number cannot be assigned.
- Beginner translation: Small does not automatically mean predictable. A two-amino-acid molecule may be degraded quickly, transported, or metabolized differently depending on route.
- Practical interpretation: Do not borrow half-lives from Epithalon, Thymogen, dietary dipeptides, or vendor claims. Without a validated Vilon-specific half-life, any steady-state language stays qualitative. The practical PK unknowns are absorption, first-pass degradation, tissue distribution, intracellular access, renal clearance, and whether any observed cell-culture effect requires concentrations that are achievable in humans. Those questions have to be answered before meaningful accumulation or washout timing can be stated.
- As a dipeptide, systemic persistence may be short, and proposed effects are downstream. Half-life calculators are not a useful efficacy model. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Vilon is commonly grouped with Epithalon, Thymalin, Thymogen, Pinealon, and other short bioregulators. The logic is usually “organ-system signaling” or immune-aging support, which is not the same as controlled evidence that combining them improves outcomes.
- Vilon is separate from Thymosin Alpha-1. Thymosin Alpha-1 has a more recognizable clinical immunology literature and regulatory history in some countries.
- Vilon is an ultrashort dipeptide with a much less established human evidence base.
- Stacking the two can make immune-marker interpretation unclear.
- Use caution around immunosuppressants, autoimmune disease, transplant medicine, active infection, active cancer treatment, and vaccine-response questions.
- In those contexts, immune modulation is not automatically beneficial, and a clinician should direct care.
- Stacking with the aforementioned peptides can create a story of rejuvenation without measurable endpoints. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Modern, large human safety datasets are lacking.
- Potential risks include allergic or injection-site reactions, product contamination, endotoxin exposure, and unpredictable immune effects in susceptible people.
- Oral products may have different risks than injectable products, but lower route risk does not prove efficacy.
- Avoid casual use in pregnancy, breastfeeding, children, active cancer, unexplained weight loss, autoimmune flare, transplant recipients, severe immunodeficiency, or concurrent chemotherapy/immunotherapy unless part of formal clinical care.
- These cautions reflect the uncertainty around immune and cell-survival signaling, not a proven specific toxicity.
- Cancer-prevention claims deserve special caution.
- Animal tumor findings are not an invitation to use Vilon for human cancer prevention or treatment.
- Anyone with cancer risk, cancer history, or abnormal screening results needs standard medical evaluation, not peptide substitution.
- Short sequence does not equal proven safety. Immune modulation, unknown long-term effects, and product authenticity are the main concerns. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- For immune/inflammation research framing, useful markers may include CBC with differential, hs-CRP, ESR, infection frequency, vaccine-response history when medically indicated, immunoglobulins in suspected immune deficiency, and clinician-selected lymphocyte subsets.
- Cytokine panels can be noisy, so one reading does not support strong conclusions.
- For aging or recovery claims, use objective endpoints rather than vague “immune boost” language: illness frequency, recovery time, sleep, training load, medication changes, body weight, and inflammatory markers.
- For oncology-adjacent claims, standard screening and oncology follow-up are the monitoring plan; Vilon-specific self-monitoring is not enough.
- For safety, document route, lot number, COA, endotoxin result if injectable, start/stop dates, new symptoms, rash, fever, lymph-node swelling, infection pattern, and any changes in autoimmune symptoms.
- Track infection patterns, CBC if immune goals are claimed, sleep/energy, and general health markers. Do not rely on vague anti-aging impressions. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- Vilon is not an FDA-approved drug with a labeled therapeutic indication.
- It may appear as a research peptide, a bioregulator supplement, or a gray-market product depending on jurisdiction.
- Those categories do not provide the same assurance as an approved medicine.
- Anti-doping: Vilon is not treated here as athlete-safe.
- Even when not specifically named, a non-approved biologically active peptide may fall under S0 non-approved-substance risk.
- Competitive athletes should verify current status with WADA/USADA or their sport’s anti-doping authority.
- Vilon is not FDA-approved. Regional bioregulator use is not U.S. therapeutic validation. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.